Molecular Analysis in a Glioblastoma Cohort—Results of a
Prospective Analysis

Liverana Lauretti; Tonia Cenci; Nicola Montano; Martina Offi; Martina Giordano; Valerio M. Caccavella; Antonella Mangraviti; Ludovico Agostini; 1 Alessandro Olivi; Lucia Gabriele; Luigi Maria Larocca; Roberto Pallini; Maurizio Martini; Quintino Giorgio D'Alessandris

Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis

Liverana Lauretti, Tonia Cenci, Nicola Montano, Martina Offi, Martina Giordano, Valerio M. Caccavella, Antonella Mangraviti, Ludovico Agostini, 1 Alessandro Olivi, Lucia Gabriele, Luigi Maria Larocca, Roberto Pallini, Maurizio Martini, Quintino Giorgio D'Alessandris

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively activated oncogenic receptor, in glioblastoma is controversial. We performed a prospective study enrolling 355 patients operated on for de novo glioblastoma at a large academic center. The molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression, was assessed. Standard parameters (age, clinical status and extent of surgical resection) were confirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved survival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened prognosis. Interestingly, female sex was associated with a better outcome. Such findings are of interest for the design of future trials.

Lingua originale	English
pagine (da-a)	N/A-N/A
Numero di pagine	8
Rivista	Journal of Personalized Medicine
Stato di pubblicazione	Pubblicato - 2022

Keywords

EGFRvIII
VEGF
female
glioblastoma
trial population

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{57184671b878420dbfd9077cf7413fd2,

title = "Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis",

abstract = "The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively activated oncogenic receptor, in glioblastoma is controversial. We performed a prospective study enrolling 355 patients operated on for de novo glioblastoma at a large academic center. The molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression, was assessed. Standard parameters (age, clinical status and extent of surgical resection) were confirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved survival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened prognosis. Interestingly, female sex was associated with a better outcome. Such findings are of interest for the design of future trials.",

keywords = "EGFRvIII, VEGF, female, glioblastoma, trial population, EGFRvIII, VEGF, female, glioblastoma, trial population",

author = "Liverana Lauretti and Tonia Cenci and Nicola Montano and Martina Offi and Martina Giordano and Caccavella, {Valerio M.} and Antonella Mangraviti and Ludovico Agostini and {Alessandro Olivi}, 1 and Lucia Gabriele and Larocca, {Luigi Maria} and Roberto Pallini and Maurizio Martini and D'Alessandris, {Quintino Giorgio}",

year = "2022",

language = "English",

pages = "N/A--N/A",

journal = "Journal of Personalized Medicine",

issn = "2075-4426",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

}

TY - JOUR

T1 - Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis

AU - Lauretti, Liverana

AU - Cenci, Tonia

AU - Montano, Nicola

AU - Offi, Martina

AU - Giordano, Martina

AU - Caccavella, Valerio M.

AU - Mangraviti, Antonella

AU - Agostini, Ludovico

AU - Alessandro Olivi, 1

AU - Gabriele, Lucia

AU - Larocca, Luigi Maria

AU - Pallini, Roberto

AU - Martini, Maurizio

AU - D'Alessandris, Quintino Giorgio

PY - 2022

Y1 - 2022

N2 - The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively activated oncogenic receptor, in glioblastoma is controversial. We performed a prospective study enrolling 355 patients operated on for de novo glioblastoma at a large academic center. The molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression, was assessed. Standard parameters (age, clinical status and extent of surgical resection) were confirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved survival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened prognosis. Interestingly, female sex was associated with a better outcome. Such findings are of interest for the design of future trials.

AB - The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively activated oncogenic receptor, in glioblastoma is controversial. We performed a prospective study enrolling 355 patients operated on for de novo glioblastoma at a large academic center. The molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression, was assessed. Standard parameters (age, clinical status and extent of surgical resection) were confirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved survival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened prognosis. Interestingly, female sex was associated with a better outcome. Such findings are of interest for the design of future trials.

KW - EGFRvIII

KW - VEGF

KW - female

KW - glioblastoma

KW - trial population

KW - EGFRvIII

KW - VEGF

KW - female

KW - glioblastoma

KW - trial population

UR - http://hdl.handle.net/10807/201844

M3 - Article

SN - 2075-4426

SP - N/A-N/A

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

ER -

Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis

Abstract

Keywords

Altri file e collegamenti

Fingerprint

Cita questo